Investigational drug · Phase 2
sabatolimab
Also called: MBG453
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
17
Any phase or sponsor naming "sabatolimab"
First trial start
2023
Feb 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "sabatolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Approved drugs for the same conditions: Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "sabatolimab" as an intervention, largest first.
- Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)Pivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT04266301 · 530 participants · Start Jun 8, 2020 · Primary completion Oct 2, 2024
Drug: Sabatolimab; Azacitidine and 1 more · For: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
Sites: Yuma, Arizona; Los Angeles, California; New Haven, Connecticut · 149 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02608268 · 252 participants · Start Nov 23, 2015 · Primary completion Aug 30, 2022
Drug: MBG453; PDR001 and 1 more · For: Advanced Malignancies
Sites: Baltimore, Maryland; Boston, Massachusetts; Houston, Texas · 14 sites in all
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03066648 · 241 participants · Start Jul 6, 2017 · Primary completion Sep 8, 2023
Drug: Decitabine; PDR001 and 2 more · For: Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute and 5 more
Sites: Boston, Massachusetts; Portland, Oregon; Houston, Texas · 11 sites in all
- A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).Pivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03946670 · 127 participants · Start Jun 4, 2019 · Primary completion Apr 26, 2022
Drug: MBG453; Placebo and 1 more · For: Myelodysplastic Syndromes
Sites: Duarte, California; New Haven, Connecticut; Boston, Massachusetts · 48 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04150029 · 90 participants · Start Sep 1, 2020 · Primary completion Oct 25, 2024
Drug: MBG453; Venetoclax and 1 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; New Haven, Connecticut; Iowa City, Iowa · 28 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03940352 · 52 participants · Start Jun 24, 2019 · Primary completion Aug 20, 2024
Drug: HDM201; MBG453 and 1 more · For: Acute Myeloid Leukemia (AML); High-risk Myelodysplastic Syndrome (MDS)
Sites: Durham, North Carolina; Melbourne, Australia; Helsinki, Finland · 9 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04097821 · 45 participants · Start Sep 26, 2019 · Primary completion May 3, 2023
Drug: Ruxolitinib; Siremadlin and 4 more · For: Myelofibrosis
Sites: Adelaide, Australia; Melbourne, Australia; Toronto, Canada · 22 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04878432 · 39 participants · Start Mar 17, 2022 · Primary completion Oct 26, 2023
Drug: MBG453; Azacitidine and 2 more · For: Myelodysplastic Syndrome (MDS)
Sites: Phoenix, Arizona; Tucson, Arizona; Denver, Colorado · 15 sites in all
- Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.Active, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT05201066 · 33 participants · Start Feb 28, 2023 · Primary completion Feb 14, 2028
Drug: decitabine; spartalizumab and 4 more · For: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic
Sites: Portland, Oregon; Salt Lake City, Utah; Clayton, Australia · 24 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04810611 · 33 participants · Start Jun 18, 2021 · Primary completion Apr 19, 2024
Drug: MBG453; NIS793 and 1 more · For: Myelodysplastic Syndromes
Sites: Duarte, California; Tampa, Florida; Boston, Massachusetts · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- TIM3 Blockade with Hypomethylating Therapy Restores NK Cell and Cytotoxic CD4+ T-cell Activity in Patients with AML or MDS.
Huuhtanen J, Forstén S, Ford B, et al. · Cancer Immunol Res 2026
- Νοvel Therapies in High-Risk Myelodysplastic Syndromes.
Galanopoulos AG, Papi C · Eur J Haematol 2026
- TIM-3 in AML: a janus-faced orchestrator of immune exhaustion and leukemic self-renewal.
Hjazi A · Cancer Cell Int 2026
- Mechanism of AGEs-RAGE axis inhibition of ferroptosis in type 2 diabetic colon cancer by regulatory CEACAM1.
Liu K, Liu S, Wang D, et al. · Sci Rep 2026
- TIM-3 in AML: pathogenic roles and therapeutic targetability.
Zhong L, Soleimani Samarkhazan H · Clin Exp Med 2026
- The conundrum of drug development in higher-risk MDS: lessons learned from recently failed phase 3 clinical trials.
Stahl M, Zeidan AM · Blood 2026
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.